We have located links that may give you full text access.
DF3 (CA15-3) antibody as a marker of cutaneous adnexal tumors.
Acta Dermato-venereologica 1994 March
DF3(CA15-3) monoclonal antibody detects the 20 amino acid sequence of epithelial mucin. In normal cutaneous tissue DF3 antibody exhibits strong and constant positive reactivity with sebaceous and secretory segments of eccrine and apocrine sweat glands. All epidermal tumors are DF3 negative but poorly differentiated squamous cell carcinoma. Various adnexal tumors such as eccrine hidrocystoma, tubular apocrine adenoma, syringocystadenoma papilliferum, eccrine poroma, eccrine spiradenoma, clear cell hidradenoma, mixed cell tumor, eccrine porocarcinoma, extramammary Paget's disease and adenoid cystic carcinoma are DF3 positive, which indicates epithelial mucin production by these tumors.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app